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Abstract
Purpose Protecting the heart from ischaemia-reperfusion (IR) injury is a major goal in patients presenting with an acute myo-
cardial infarction. Pyroptosis is a novel form of cell death in which caspase 1 is activated and cleaves interleukin 1β. VX-785 is a
highly selective, prodrug caspase 1 inhibitor that is also clinically available. It has been shown to be protective against acute IR
in vivo rat model, and therefore might be a promising possibility for future cardioprotective therapy. However, it is not known
whether protection by VX-765 involves the reperfusion injury salvage kinase (RISK) pathway. We therefore investigated
whether VX-765 protects the isolated, perfused rat heart via the PI3K/Akt pathway and whether protection was additive with
ischaemic preconditioning (IPC).
Methods Langendorff-perfused rat hearts were subject to ischaemia and reperfusion injury in the presence of 30 μM VX-765,
with precedent IPC, or the combination of VX-765 and IPC.
Results VX-765 reduced infarct size (28 vs 48% control; P < 0.05) to a similar extent as IPC (30%; P < 0.05). The PI3 kinase
inhibitor, wortmannin, abolished the protective effect of VX-765. Importantly in the model used, we were unable to show
additive protection with VX-765 + IPC.
Conclusions The caspase 1 inhibitor, VX-765, was able to reduce myocardial infarction in a model of IR injury. However, the
addition of IPC did not demonstrate any further protection.
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Introduction
Protecting the heart from ischaemia-reperfusion injury is a
major goal in patients presenting with an acute myocardial
infarction. To date, it has been shown experimentally that
protection against ischaemia-reperfusion (IR) injury can be
mitigated by activating the reperfusion injury salvage kinase
(RISK) pathway. However, in order to maximise such
protection, it is important to identify non-RISK pathways that
could be additive [1, 2].
Pyroptosis is a novel form of cell death in which caspase 1 is
activated and cleaves interleukin 1β. The resulting IL1-β and IL-
18 protein fragments are released from the cell via gasdermin D
cell membrane pores [3]. In addition to stimulating an immune
response, the released cytokinesmay potentially have amultiply-
ing effect in stimulating death of local cardiomyocytes.
Importantly, after myocardial IR, caspase 1 can be activated in
both cardiomyocytes and cardiac fibroblasts, the major cell pop-
ulations of the cardiac muscle [4, 5]. However, whether
pyroptosis contributes to ischaemia-reperfusion injury has not
been definitively established. The highly selective prodrug cas-
pase 1 inhibitor, VX-765, has been shown to be protective
against acute IR in vivo rat model [6]. This specific class of
caspase inhibitor might be a promising possibility for future
cardioprotective therapy [3]. However, it is not known whether
VX-765 requires activation of known pro-survival kinases such
as the phosphatidylinositol-3-kinase (PI3K)-Akt, one of the most
prominent pro-survival signalling pathways associated with the
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RISK pathway which is known to protect against the damage
caused by acute IR [7–9]. Interestingly, a well-known example of
this is the phenomenon of ischaemic preconditioning (IPC) [10].
Therefore, in this study, we assessed the protective effect of
the caspase 1 inhibitor, VX-765, in the presence of a PI3
kinase inhibitor. In addition, because of its well-defined mech-
anism of cardioprotection via the RISK pathway, we admin-
istered IPC simultaneously with VX-765 to ascertain whether
this would result in additional protection against acute IR. The
aim of this study was to determine whether caspase 1 inhibi-
tion could function via a different or complementary pathway
to that of PI3K-Akt activation.
Method
Male Sprague Dawley rats (300–350 g) were used according
to UK (Scientific Procedures) Act of 1986. All animals re-
ceived sodium pentobarbital (60 mg/kg) anaesthesia and a
single dose of sodium heparin (0.1 UI). Following anaesthe-
sia, the hearts were excised and retrogradely perfused with
Krebs Henseleit buffer (mM: 118, NaCl; 25, NaHCO3; 11,
D-glucose; 4.7, KCl; 1.22 MgSO4·7H2O; 1.21, KH2PO4;
1.84 CaCl2·2H2O) bubbled with carbogen (95 O2 and 5%
CO2) at 37 °C and pH 7.4. The protocol applied was 40-min
stabilisation followed by 35-min regional ischaemia with left
anterior descending coronary artery occlusion and 2 h of re-
perfusion. The hearts were assigned to one of the following
seven groups: (1) control-vehicle dimethyl sulfoxide (the sol-
vent for VX-765); (2) IPC, consisting of 3 × 5-min cycles of
ischaemia and reperfusion; (3) VX-765, (30 μM) given after
10-min stabilisation and throughout the ischaemia and reper-
fusion period; (4) control+W, control-vehicle group given
wortmannin (100 nM) for 15 min at reperfusion; (5) IPC+W,
IPC group followed by 15 min of wortmannin (100 nM) at
reperfusion; (6) VX-765+W, VX-765 group followed by
15 min of wortmannin (100 nM) at reperfusion; (7) VX-
765+IPC group, both VX-765 and IPC treatments given to-
gether. At the conclusion of the experiment, the analysis of
infarct size (IS), as a proportion of area at risk (AAR), was
calculated via planimetry using image J software (version
1.45, National Institutes of Health, USA). Infarct size was
Fig. 1 Area-at-risk as percentage
of LVarea, represented as scatter
plot with bar graphs with a mean
and standard error of the mean
(SEM), and number of hearts in
each group as indicated
Fig. 2 Infarct size as a percentage
of area-at-risk represented as
scatter plot and mean + standard
error of the mean (SEM), with the
number of hearts in each group
indicated. The data was analysed
by nonparametric Kruskal–Wallis
test (one-way ANOVA) with
Dunn’s multiple comparisons
post hoc test. *P < 0.05 IPC, VX-
765 and VX-765 vs control-
vehicle; #P < 0.05 IPC, VX-765
and VX-765 vs control + W
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calculated a percentage of the area-at-risk (IS/AAR). Results
were compared by nonparametric Kruskal–Wallis test (one-
way ANOVA) with Dunn’s multiple comparisons post hoc
test.
Results
A total of 52 animals were used of which 3 were excluded due
to lack of perfusion at the beginning of the protocol. The
ischaemic area at risk was the same in all groups (Fig. 1).
VX-765 reduced infarct size (28 vs 48% control-vehicle;
P < 0.05) to a similar extent as IPC (30%; P < 0.05 compared
to the control-vehicle group) (Fig. 2). Wortmannin, a non-
specific PI3 kinase inhibitor, abolished the protective effect
of VX-765 when given for 15 min at reperfusion (Fig. 2).
Importantly in the model used, we were unable to show an
additive protective effect with VX-765 + IPC (Fig. 2).
Discussion
The present study assessed whether the caspase-1 inhibitor
VX-765 could protect isolated hearts undergoing acute IR
injury. The aim was to ascertain whether such inhibition is
associated with the activation of PI3K-Akt and hence a
conditioning-like mechanism or alternatively if it functioned
via a mechanism independent of PI3K-Akt.
When activated, the majority of caspases result in apoptotic
cell death. Importantly, caspase 1 has also been implicated in
pyroptosis. IPC, as a trigger for pro-survival kinases, is asso-
ciated with protection against necrosis, although there is also
some evidence that it can inhibit the activation of other cell
death pathways such as apoptosis [11]. In order to maximise
the degree of protection in the setting of acute myocardial
infarction, it is necessary to establish whether additional phar-
macological approaches are able to elicit protection indepen-
dent of the known phenomenon of IPC. Therefore, the poten-
tial for co-treatment with the caspase 1 inhibitor VX-765 and
IPC was studied; such an approach was recently proposed and
shown by Yang XM et al. using VX-765 plus the antiplatelet
inhibitor Cangrelor [6].
However, in our study we showed that the protective effect
of the prodrug, VX-765, was abolished by the PI3 kinase
inhibitor, wortmannin. This demonstrates that this caspase 1
inhibitor appears to involve the samemechanism of protection
as IPC: i.e. the PI3 kinase pathway. Furthermore, we were
unable to demonstrate any additive protectionwhen both treat-
ments were administered together, suggesting that they both
protect the heart via the same mechanism. The mechanism by
which VX-765 activates PI3 kinase is not known, but may be
either a consequence of caspase 1 inhibition or an off-target
effect of the drug.
Infarct size has been assumed as a relevant endpoint in
studies assessing the protective effect of agents in the setting
of ischaemia-reperfusion injury. However, an experimental
design using a single IR protocol may not fully predict the
outcome. The present study used a protocol of 35-min region-
al ischaemia followed by 2-h reperfusion, which resulted in
~48% infarct size in control-vehicle group and an infarct size
reduction to ~30% for both IPC and 28% for VX-765. It could
be argued that in order to reveal any further reduction in in-
farct size, an extended ischaemic time (e.g. 60 min) may be
necessary. In this regard, the translational value of the results
remains to be demonstrated. In addition, it must be appreciat-
ed that Western blot analysis was not performed to confirm
activation of the RISK pathway.
To summarise, we were able to demonstrate that the cas-
pase 1 inhibitor, VX-765, was able to reduce myocardial in-
farction in a model of ischaemia-reperfusion injury. However,
the addition of IPC did not demonstrate any additional
protection.
Funding Mr. Helison Rafael Pereira do Carmo was awarded a scholar-
ship from the CAPES Foundation according to the program PDSE—
88881.134023/2016-01 (Brazil). This work was supported by the
Biomedical Research Council (BRC233/CM/SD/101320).
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Ethical Approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Hausenloy DJ, Garcia-Dorado D, Botker HE, Davidson SM,
Downey J, Engel FB, et al. Novel targets and future strategies for
acute cardioprotection: position paper of the European Society of
Cardiology Working Group on Cellular Biology of the Heart.
Cardiovasc Res. 2017;113(6):564–85.
2. Hausenloy DJ, Yellon DM. Combination therapy to target reperfu-
sion injury after ST-segment-elevation myocardial infarction: a
more effective approach to cardioprotection. Circulation.
2017;136(10):904–6.
3. Kloner RA, Brown DA, Csete M, Dai W, Downey JM, Gottlieb
RA, et al. New and revisited approaches to preserving the reper-
fused myocardium. Nat Rev Cardiol. 2017;14(11):679–93.
4. Zhang W, Xu X, Kao R, Mele T, Kvietys P, Martin CM, et al.
Cardiac fibroblasts contribute to myocardial dysfunction in mice
Cardiovasc Drugs Ther
with sepsis: the role of NLRP3 inflammasome activation. PLoS
One. 2014;9(9):e107639.
5. Sandanger O, Ranheim T, Vinge LE, Bliksoen M, Alfsnes K,
Finsen AV, et al. The NLRP3 inflammasome is up-regulated in
cardiac fibroblasts and mediates myocardial ischaemia-
reperfusion injury. Cardiovasc Res. 2013;99(1):164–74.
6. Yang XM, Downey JM, Cohen MV, Housley NA, Alvarez DF,
Audia JP. The highly selective caspase-1 inhibitor VX-765 provides
additive protection against myocardial infarction in rat hearts when
combined with a platelet inhibitor. J Cardiovasc Pharmacol Ther.
2017;22(6):574–8.
7. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling
via the reperfusion injury signalling kinase (RISK) pathway links
closure of the mitochondrial permeability transition pore to
cardioprotection. Int J Biochem Cell Biol. 2006;38(3):414–9.
8. Rossello X, Riquelme JA, Davidson SM, Yellon DM. Role of PI3K
in myocardial ischaemic preconditioning: mapping pro-survival
cascades at the trigger phase and at reperfusion. J Cell Mol Med.
2017;22(2):926–35.
9. Rossello X, Riquelme JA, He Z, Taferner S, Vanhaesebroeck B,
Davidson SM, et al. The role of PI3Kalpha isoform in
cardioprotection. Basic Res Cardiol. 2017;112(6):66.
10. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic pre-
conditioning protects by activating prosurvival kinases at reperfu-
sion. Am J Physiol Heart Circ Physiol. 2005;288(2):H971–6.
11. Iliodromitis EK, Lazou A, Kremastinos DT. Ischemic precondition-
ing: protection against myocardial necrosis and apoptosis. Vasc
Health Risk Manag. 2007;3(5):629–37.
Cardiovasc Drugs Ther
